Image of an engineered mechanical yellow and magenta butterfly on a synovial sarcoma tumor

A dramatic change in treatment as the first and only, single-infusion, engineered TCR T-cell therapy1,2

TECELRA is the first FDA-approved T‑cell therapy designed to enhance TCR affinity and specificity1

Autologous T cells are transduced with a lentiviral vector to create TECELRA, which expresses MAGE‑A4-specific affinity-enhanced TCRs on the surface of the cells1

  • MAGE‑A4 is a cancer-testis antigen that is expressed on the inside of the cell, peptides of which are presented on the cell surface to facilitate immune tolerance1,3
  • MAGE‑A4 has restricted expression in normal tissues and is expressed in synovial sarcoma1
Image of an enhanced TCR on a TECELRA engineered T cell close to an HLA-A*02-presented MAGE-A4 peptide on a cancer cell
DETECT
The engineered TCR on the TECELRA cell recognizes an HLA-A*02-presented MAGE‑A4 peptide1,†​
Image of an enhanced TCR on a TECELRA engineered T cell interlocking with the HLA-A*02-presented MAGE-A4 peptide on a cancer cell
TARGET
Through engineering, the TCR’s enhanced ability to target cancer cells with precision creates an improved interaction between the TCR and the target peptide HLA complex† while minimizing recognition of normal cells1,4
Image of TECELRA engineered TCR T cells destroying cancer cells
DESTROY
Antigen-specific activation of TECELRA via the engineered TCRs enables a patient’s own T cells to destroy HLA‑A*02†/​MAGE‑A4­–expressing cancer cells through T-cell proliferation and cytokine secretion1
TECELRA is the first single‑infusion therapy that leverages the patient’s immune system to detect, target, and destroy SyS cells1
HLA=human leukocyte antigen; MAGE=melanoma-associated antigen; SyS=synovial sarcoma; TCR=T-cell receptor.
† In patients who are positive for HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P, and negative for HLA-A*02:05P.1
More info about TECELRA
Illustrated icon of a test tube, microscope slide plate, and checklist Learn about biomarker testing for eligibility Illustrated icon of a journey between two location pins Get a comprehensive overview of the TECELRA treatment process Illustrated icon of a magnifying glass looking at a graph See the response rates from the clinical trial